Podcast Elyse Park, PhD @PsycholERPark @MGH_HPRIR @AmericanCancer @MassGeneralNews #ASCO22 #OncoTwitter The Childhood...

1 year 6 Views

Elyse R. Park, Ph.D., MSPH, Associate Director of the MGH Survivorship Program & I direct the MGH Medicine/Psychiatry HPRIR program, Harvard Medical School at Harvard University. In this video, she speaks about the ASCO 2022 Abstract - A health insurance navigation intervention tool (HINT) for survivors of childhood cancer: Randomized pilot trial results from the Childhood Cancer Survivor Study.


The Childhood Cancer Survivor Study (CCSS) will look into the long-term impact of cancer and its treatments. A multi-institutional partnership will perform a retrospective cohort study that will involve the identification and active follow-up of roughly 50,000 cancer survivors diagnosed before the age of 21 between 1970 and 1999, as well as 10,000 sibling controls. This project will investigate children and young people who have been subjected to specific therapeutic modalities such as radiation, chemotherapy, and/or surgery and are at an elevated risk of long-term unfavorable health consequences. A set of sibling controls will be identified, and data will be collected for comparison.